RBC Capital raised the firm’s price target on Cidara Therapeutics (CDTX) to $35 from $31 and keeps an Outperform rating on the shares. Following the company’s virtual R&D day, the firm has come away impressed by the thoroughly mapped-out blueprint, covering NAVIGATE’s enhanced statistical plan, potential phase 3 trial design, the strategy to drive CD388’s commercial effectiveness as well as government stockpiling potential, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Cidara Therapeutics price target raised to $50 from $35 at Guggenheim
- Promising Developments and Upcoming Data Release Drive Buy Rating for Cidara Therapeutics
- Cidara Therapeutics’ CD388 Progress and Challenges Highlighted in Earnings Call
- Cidara Therapeutics price target raised to $35 from $33 at Guggenheim
- Promising Outlook for Cidara Therapeutics: Buy Rating Affirmed Amid Upcoming R&D Insights and Strategic FDA Engagement
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue